Injectable microgels containing genetically engineered bacteria for colon cancer therapy through programmed Chemokine expression.
Ontology highlight
ABSTRACT: Chemokines are emerging as important targets for cancer immunotherapy due to their role in regulating immune cell migration and activation within the tumor microenvironment. Effective delivery and sustained presence of chemokines at the tumor site is essential for recruiting and activating immune cells to exert anti-tumor effects. In this study, we report a genetically engineered bacterial cell factory designed for the continuous production of chemokine CCL21 in a controlled manner. To decrease the formation of infusion bodies (IBs) in bacteria, we used thioredoxin (Trx) as the fusion partner and cloned at N-terminal of the target protein. The commonly used promoters, pT7-LacO, pBV220, and pDawn, were employed to explore the influence of various inducers on the expression of CCL21 in bacte
SUBMITTER: Chen Y
PROVIDER: S-EPMC11609523 | biostudies-literature | 2024 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA